Fig. 4. Mean EORTC QLQ-C30 scores for symptom scales in patients in the pertuzumab plus trastuzumab and chemotherapy arm (solid line) or the placebo plus trastuzumab and chemotherapy arm (dashed line).

a Fatigue. b Dyspnoea. c Appetite loss. The numbers below the graphs indicate the number of patients who completed the scale. Higher scores indicate worse/deteriorating symptoms. Horizontal lines indicate the level at which the change from baseline was considered clinically meaningful,¹² with asterisks indicating time points where there was a clinically meaningful change. The lines are slightly offset to improve visibility, but time points are the same for each arm. ^aFor patients receiving anthracycline-based chemotherapy, the actual time point was week 10 or week 13 of HER2-targeted treatment (depending on the chemotherapy regimen given). For patients receiving non-anthracycline-based chemotherapy (i.e., the pertuzumab plus trastuzumab and docetaxel–carboplatin regimen), this was week 19 of HER2-targeted treatment. EORTC QLQ-C30 European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire, Core module, version 3, FU follow-up, mo months.